Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
RSC Adv ; 14(11): 7728-7739, 2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38444966

ABSTRACT

This work examines the hydrodeoxygenation (HDO) activity of non-edible oils using a high surface area catalyst. The HDO activity was thoroughly examined and contrasted using the high surface area catalyst Ni/Pt-ZSM-5 as well as other supports like MCM-48 and H-beta. Ni/Pt bimetals supported on mesoporous ZSM-5 were created via reverse order impregnation to facilitate HDO of non-edible oils. Techniques such as XRD, FT-IR, BET, HR-TEM, HR-SEM, TPD, and TGA were used to characterize the produced catalysts. The synthesized catalysts considerably influenced the hydrodeoxygenation activities for the synthesis of lengthy chain hydrocarbons in a stainless-steel reactor with a high-pressure fixed bed between 300 and 375 °C under 10-40 bar hydrogen pressure. High levels of Ni/Pt-ZSM-5 acidity, textural, and H2 consumption qualities were discovered. Distributions of the products were also reviewed, along with comparisons of the structure-activity connections.

2.
Curr Med Chem ; 19(36): 6207-13, 2012.
Article in English | MEDLINE | ID: mdl-22834822

ABSTRACT

The main challenge encountered while treating using Paclitaxel (PTX) is its poor solubility in aqueous solutions. The cremophor used in the formulation can cause various side effects such as hypersensitivity, myelosuppression and neurotoxicity and also leads to non-specific distribution in tumor and normal tissues. Since the structure of Paclitaxel does not possess a functional group, it is not easy to manipulate to enhance the solubility. Such limitations can be overcome by delivering Paclitaxel with the aid of drug delivery systems such as polymeric micelles, nanoparticles, hydrogels and liposomes. The review discusses various approaches of Paclitaxel delivery via polymeric nanoparticles. It focuses on the passive and active targeting of Paclitaxel.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Drug Carriers/chemistry , Nanoparticles/chemistry , Neoplasms/drug therapy , Paclitaxel/administration & dosage , Polymers/chemistry , Antibodies/immunology , Aptamers, Nucleotide/chemistry , Aptamers, Nucleotide/metabolism , Folic Acid/chemistry , Folic Acid/metabolism , Humans , Hydrogen-Ion Concentration , Peptides/chemistry , Peptides/metabolism , Receptors, Vascular Endothelial Growth Factor/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...